Open Access

Antitumor efficacy of the Runx2‑dendritic cell vaccine in triple‑negative breast cancer in vitro

  • Authors:
    • Mi Tang
    • Yu Liu
    • Qiao‑Chu Zhang
    • Peng Zhang
    • Jue‑Kun Wu
    • Jia‑Ni Wang
    • Ying Ruan
    • Yong Huang
  • View Affiliations

  • Published online on: June 21, 2018     https://doi.org/10.3892/ol.2018.9001
  • Pages: 2813-2822
  • Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Triple‑negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis and limited effective treatment. The rise in immunotherapeutic strategies prompted the establishment of a genetic vaccine against TNBC in vitro using a possible biological marker of TNBC. In the present study, different detection methods were used to evaluate the distribution and expression of runt‑associated transcription factor 2 (Runx2) in various breast cancer cell lines. Following the development of the Runx2‑dendritic cell (DC) vaccine using a lentivirus, the transfection efficacy was recorded. The T lymphocytes co‑cultured with the vaccine were collected to assess the antitumor potency. Increased levels of Runx2 were expressed in breast cancer cells; however, different breast cancer cell lines expressed various levels of Runx2. Runx2 demonstrated particularly high expression in TNBC cells, compared with non‑TNBC cells. A Runx2 lentivirus transfection system was successfully engineered, and Runx2 was transduced into dendritic cells whilst maintaining stable expression. The sustained and stable cytotoxic T cells induced in the transfected group had higher and more specific antitumor efficacy against TNBC, compared with the other cell lines. Runx2 may be a novel target for TNBC treatment. The Runx2‑DC vaccine may induce specific and efficient antitumor effects in TNBC in vitro.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tang M, Liu Y, Zhang QC, Zhang P, Wu JK, Wang JN, Ruan Y and Huang Y: Antitumor efficacy of the Runx2‑dendritic cell vaccine in triple‑negative breast cancer in vitro. Oncol Lett 16: 2813-2822, 2018.
APA
Tang, M., Liu, Y., Zhang, Q., Zhang, P., Wu, J., Wang, J. ... Huang, Y. (2018). Antitumor efficacy of the Runx2‑dendritic cell vaccine in triple‑negative breast cancer in vitro. Oncology Letters, 16, 2813-2822. https://doi.org/10.3892/ol.2018.9001
MLA
Tang, M., Liu, Y., Zhang, Q., Zhang, P., Wu, J., Wang, J., Ruan, Y., Huang, Y."Antitumor efficacy of the Runx2‑dendritic cell vaccine in triple‑negative breast cancer in vitro". Oncology Letters 16.3 (2018): 2813-2822.
Chicago
Tang, M., Liu, Y., Zhang, Q., Zhang, P., Wu, J., Wang, J., Ruan, Y., Huang, Y."Antitumor efficacy of the Runx2‑dendritic cell vaccine in triple‑negative breast cancer in vitro". Oncology Letters 16, no. 3 (2018): 2813-2822. https://doi.org/10.3892/ol.2018.9001